[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasopharyngeal-carcinoma-by-ajcc-v8-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasopharyngeal-carcinoma-by-ajcc-v8-stage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,67,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100555201","phase-2-nimotuzumab-combined-with-tgp-as-first-line-therapy-in-patients-with-recurrentmetastatic-nasopharyngeal-carcinoma-100555201",false,"NCT06509009","Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","Nimotuzumab Combined With Toripalimab\u002FGemcitabine\u002FCisplatin as First-line Therapy in Patients With Recurrent\u002FMetastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Clinical Study","Inclusion Criteria:\n\nSigned written informed consent form.\n\nAge between 18 and 75 years, inclusive, without gender restriction.\n\nHistologically confirmed diagnosis of recurrent\u002Fdistant metastasis nasopharyngeal carcinoma, first line patients and unsuitable for local operation treatment.\n\nEGFR expression positive.\n\nPresence of at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and patients who have not undergone definitive treatment.\n\nECOG Performance Status (PS) score of 0 or 2.\n\nExpected survival duration of at least 3 months.\n\nWhite blood cell count ≥ 3 × 10\\^9\u002FL; absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; platelet count ≥ 100 × 10\\^9\u002FL; hemoglobin level ≥ 90 g\u002FL.\n\nSerum creatinine level ≤ 1.2 mmol\u002FL or creatinine clearance ≥ 60 ml\u002Fmin.\n\nSerum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (in case of liver metastasis, ≤ 3.0 × ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (in case of liver metastasis, ≤ 5.0 × ULN).\n\nFemale patients must have a negative urine pregnancy test prior to study enrollment (this criterion does not apply to patients with bilateral ovarian resection and\u002For hysterectomy or postmenopausal patients).\n\n\\-\n\nExclusion Criteria:\n\nSubjects who have received radiotherapy, chemotherapy, immunosuppressive agents, monoclonal antibodies, oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), or anti-angiogenic drugs within the past six months.\n\nSubjects who have participated in another interventional clinical trial, undergone major surgical procedures, or scheduled for surgery within 30 days prior to screening.\n\nPatients with severe underlying diseases that preclude tolerance to the treatment.\n\nHistory of other malignancies, except for cured cervical carcinoma in situ, skin basal cell carcinoma, or malignancies cured for more than 5 years without recurrence.\n\nPresence of uncontrolled comorbidities such as heart failure, diabetes mellitus, hypertension, thyroid disorders, psychiatric illnesses, etc.\n\nSubjects with contraindications to immunotherapy, including those with immune dysfunction diseases (such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, HIV infection, hepatitis B, hepatitis C, chronic use of steroids for autoimmune diseases), recipients of allogeneic transplants, patients with interstitial lung disease, or those with meningeal metastasis or progressive brain metastasis.\n\nAllergy to any of the drugs or their components used in the study protocol. Grade 2 or higher peripheral neuropathy or hearing loss according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.\n\nPregnant women (confirmed by blood or urine human chorionic gonadotropin \\[HCG\\] test) or lactating mothers, or subjects of reproductive age who are unwilling or unable to adopt effective contraceptive measures until at least 6 months after the last treatment in the study.\n\n\\-","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine\u002Fcisplatin regimen treatment recurrent\u002Fdistant-metastasis nasopharyngeal carcinoma.",[27],"Nasopharyngeal Carcinoma by AJCC V8 Stage",[29],"nasopharyngeal carcinoma","RECRUITING","2025-09-16",{"date":33,"type":34},"2025-09-19","ACTUAL",{"date":36,"type":34},"2024-08-30",{"date":38,"type":21},"2027-05-30",{"name":40,"class":41},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100523397","phase-3-ctv-delineation-based-solely-on-geometric-expansion-from-gtv-in-nasopharyngeal-carcinoma-100523397","NCT06095154","CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma","CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma: A Prospective, Multi-center, Randomized Controlled Phase III Clinical Study","Inclusion Criteria:\n\n1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;\n2. No distant metastatic;\n3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;\n4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;\n5. Signing informed consent;\n6. Follow up regularly and comply with test requirements.\n\nExclusion Criteria:\n\n1. Disease progression during IMRT;\n2. Previous malignancy or other concomitant malignant diseases;\n3. The evaluation information of tumor efficacy can not be obtained;\n4. Receive blind treatment in other clinical research;\n5. Have or are suffering from other malignant tumors within 5 years (except non- melanoma skin cancer or pre-invasive cervical cancer);\n6. Serious complications, such as uncontrolled hypertension, coronary heart disease, diabetes, heart failure, etc;\n7. Active systemic infection;\n8. No or limited capacity for civil conduct;\n9. The patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study;\n10. Pregnancy or lactation period;","70 Years",{"count":52,"type":21},474,[54],"PHASE3","This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. The aim of this study is to evaluate the efficacy and safety of modified IMRT, of which CTV delineation was only based on geometric expansion from GTV.",[27],"2025-03-11",{"date":59,"type":34},"2025-03-13",{"date":61,"type":34},"2025-01-01",{"date":63,"type":21},"2030-12-31",{"name":65,"class":66},"Fujian Cancer Hospital","OTHER_GOV",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100528925","nbi-combined-with-mri-to-guide-ctv-optimization-in-eccentric-nasopharyngeal-carcinoma-100528925","NCT06167109","NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma","Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Males and females ≥18 years of age;\n2. ECOG Performance Status 0,1 or 2;\n3. Pathologically diagnosed as nasopharyngeal carcinoma;\n4. Pretreatment nasopharynx and neck MRI imaging;\n5. Nasopharyngeal suspected lesions were examined by NBI endoscopy;\n6. Meeting the definition of eccentric NPC with ipsilateral (affected side) staging of T1-4 and contralateral (healthy side) staging of T0;\n7. Patients evaluated without contraindications to radiotherapy;\n8. Voluntary participation in clinical research, and signed informed consent.\n\nExclusion Criteria:\n\n1. Patients who did not successfully undergo all three examinations (MRI, NBI, and endoscopic biopsy);\n2. Other rare pathological types, such as adenocarcinoma;\n3. Patients with tumor invasion of the clivus;\n4. Patients whose contralateral retropharyngeal lymph nodes met the diagnostic criteria;\n5. Invasion of paranasal sinuses (except simple sphenoid invasion).",{"count":75,"type":21},60,[77],"NA","This is a prospective, single-center clinical trial in eccentric nasopharyngeal carcinoma (NPC) patients. The aim of this study is to evaluate the efficacy and safety of NBI combined with MRI-guided optimized CTV compared with conventional CTV, and to compare the radiotherapy-related adverse events and quality of life between the two groups.",[27],"2023-12-04",{"date":82,"type":34},"2023-12-12",{"date":84,"type":34},"2023-10-20",{"date":86,"type":21},"2026-10",{"name":88,"class":41},"Chongqing University Cancer Hospital",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100494408","concurrent-and-adjuvant-nimotuzumab-combined-with-induction-chemotherapy-plus-chemoradiation-in-nasopharyngeal-carcinoma-100494408","NCT05717790","Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma","Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation and Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age: 18 to 70.\n2. Pathological type: non-keratinizing carcinoma (World Health Organization criteria).\n3. Diagnosed with LANPC (stage III-IV, except for patients with T3N0)) according to the 8th edition clinical staging system of the American Joint Committee on Cancer \\[AJCC\\]\u002FUnion for International Cancer Control \\[UICC\\].\n4. ECOG performance score: 0 to 1.\n5. Primary lesions can measurable.\n6. Adequate marrow function: neutrocyte count≥1.5×10e9\u002FL, hemoglobin ≥90g\u002FL and platelet count ≥100×10e9\u002FL.\n7. Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and creatinine clearance rate ≥ 50 ml\u002Fmin (Cockcroft-Gault formula).\n8. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Primary lesions or lymph node have been operated (except of operation for biopsy).\n2. Previous Received other anti EGFR monoclonal antibody treatment;Previous chemotherapy or immunization therapy.\n3. Other malignant tumor.\n4. Participation in other interventional clinical trials within 1 month.\n5. History of Serious lung or heart disease.\n6. Pregnant or breast-feeding women and women who refused to take contraceptive method.\n7. Drug abuse or alcohol addiction.\n8. History of serious allergic or allergy.\n9. Refused or can't signed informed consent form.\n10. Other patients who are considered ineligible for the study by the investigator.",{"count":97,"type":21},288,[77],"Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This is a multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of nimotuzumab combined with induction chemotherapy plus chemoradiation and adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.",[27],[102,103,104,105,106],"Nimotuzumab","Nasopharyngeal Carcinoma","Induction Chemotherapy","Chemoradiation","Adjuvant Therapy","2023-01-29",{"date":109,"type":34},"2023-02-08",{"date":111,"type":34},"2022-12-01",{"date":113,"type":21},"2027-11-30",{"name":115,"class":41},"Fourth Affiliated Hospital of Guangxi Medical University",9]